<a href="https://www.fiercebiotech.com/biotech/after-arcellx-buyout-close-gilead-trims-108-jobs-car-t-biotechs-redwood-city-outpost" hreflang="en">After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost</a>
Gilead Sciences has laid off 108 employees from Arcellx's Redwood City site following its $7.8 billion acquisition of the CAR-T biotech company, as part of workforce consolidation. The layoffs are set to begin at the end of June 2026, coinciding with Gilead's preparations for the potential launch of the CAR-T therapy anito-cel.
Gilead Sciences' acquisition of Arcellx highlights the ongoing trend of workforce consolidation following major biopharma mergers. For those tracking investment opportunities, the focus should be on Gilead's strategic move to leverage anito-cel, a BCMA-directed CAR-T therapy, pending FDA approval by December 2026. This could signal potential growth in the CAR-T market space, especially with performance-based financial incentives tied to global sales targets.